Search results for 421

Brilliant Violet 421 anti-human CD269 (BCMA) Antibody anti-CD269 - 19F2, BioLegend, 357519
Host
Mouse
Reactivity
Human
Applications
FC -Quality tested
Conjugation

Brilliant Violet 421 anti-human CD269 (BCMA) Antibody anti-CD269 - 19F2, BioLegend, 357520
Host
Mouse
Reactivity
Human
Applications
FC -Quality tested
Conjugation

Brilliant Violet 421 anti-human CD314 NKG2D Antibody anti-CD314 - 1D11, BioLegend, 320821
The 1D11 antibody blocks MICA binding to T cells, induces redirected lysis, and costimulates T cells activation and proliferation. Additional reported (for the relevant formats) applications include: immunoprecipitation1,2, blocking of ligand binding, induction of redirected cell lysis, and costimulation of T cells proliferation2-7. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 320814) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered.
Host
Mouse
Reactivity
Human
Applications
FC - Quality tested
Conjugation

Brilliant Violet 421 anti-human CD314 NKG2D Antibody anti-CD314 - 1D11, BioLegend, 320822
The 1D11 antibody blocks MICA binding to T cells, induces redirected lysis, and costimulates T cells activation and proliferation. Additional reported (for the relevant formats) applications include: immunoprecipitation1,2, blocking of ligand binding, induction of redirected cell lysis, and costimulation of T cells proliferation2-7. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 320814) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered.
Host
Mouse
Reactivity
Human
Applications
FC - Quality tested
Conjugation

Brilliant Violet 421™ anti-mouse CD19 Antibody, CD19, 1D3/CD19, BioLegend, 152421
Additional reported applications (for the relevant formats) include: blocking1,2and immunoprecipitation1.
Host
Rat
Reactivity
Mouse
Applications
FC - Quality tested
Conjugation

Brilliant Violet 421 anti-mouse TIGIT Vstm3 Antibody anti-TIGIT - 1G9, BioLegend, 142111
Host
Mouse
Reactivity
Mouse
Applications
FC -Quality tested
Conjugation

Brilliant Violet 421 anti-human CD154 Antibody anti-CD154 - 24-31, BioLegend, 310823
Additional reported applications (for the relevant formats) include: immunofluorescence microscopy1,3and blocking of T cell-dependent B cell differentiation1,2,4,5. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 310812). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 310828) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Host
Mouse
Reactivity
Human
Applications
FC - Quality tested
Conjugation

Brilliant Violet 421 anti-human CD154 Antibody anti-CD154 - 24-31, BioLegend, 310824
Additional reported applications (for the relevant formats) include: immunofluorescence microscopy1,3and blocking of T cell-dependent B cell differentiation1,2,4,5. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 310812). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 310828) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).
Host
Mouse
Reactivity
Human
Applications
FC - Quality tested
Conjugation

Brilliant Violet 421 anti-mouse CD335 NKp46 Antibody anti-CD335 - 29A1.4, BioLegend, 137611
Additional reported applications (for the relevant formats) include: immunohistochemical staining of frozen tissue sections1,2andin vitroactivation of NK cells1.
Host
Rat
Reactivity
Mouse
Applications
FC - Quality tested
Conjugation

Brilliant Violet 421 anti-mouse CD335 NKp46 Antibody anti-CD335 - 29A1.4, BioLegend, 137612
Additional reported applications (for the relevant formats) include: immunohistochemical staining of frozen tissue sections1,2andin vitroactivation of NK cells1.
Host
Rat
Reactivity
Mouse
Applications
FC - Quality tested
Conjugation
Please provide the required information below so that we can quickly source your products.
